ATE513833T1 - Thienopyridinverbindungen und verfahren zu ihrer verwendung - Google Patents

Thienopyridinverbindungen und verfahren zu ihrer verwendung

Info

Publication number
ATE513833T1
ATE513833T1 AT06737303T AT06737303T ATE513833T1 AT E513833 T1 ATE513833 T1 AT E513833T1 AT 06737303 T AT06737303 T AT 06737303T AT 06737303 T AT06737303 T AT 06737303T AT E513833 T1 ATE513833 T1 AT E513833T1
Authority
AT
Austria
Prior art keywords
methods
thienopyridine compounds
thienopyridine
compounds
hif
Prior art date
Application number
AT06737303T
Other languages
English (en)
Inventor
Eric D Turtle
Lee A Flippin
Michael P Arend
Heng Cheng
Original Assignee
Fibrogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fibrogen Inc filed Critical Fibrogen Inc
Application granted granted Critical
Publication of ATE513833T1 publication Critical patent/ATE513833T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06737303T 2005-03-02 2006-03-02 Thienopyridinverbindungen und verfahren zu ihrer verwendung ATE513833T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65813105P 2005-03-02 2005-03-02
PCT/US2006/008117 WO2006094292A2 (en) 2005-03-02 2006-03-02 Thienopyridine compounds, and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE513833T1 true ATE513833T1 (de) 2011-07-15

Family

ID=36941909

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06737303T ATE513833T1 (de) 2005-03-02 2006-03-02 Thienopyridinverbindungen und verfahren zu ihrer verwendung

Country Status (6)

Country Link
US (2) US8703795B2 (de)
EP (1) EP1866318B1 (de)
JP (2) JP4792048B2 (de)
CN (1) CN101166745A (de)
AT (1) ATE513833T1 (de)
WO (1) WO2006094292A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7848703B1 (en) 2004-12-30 2010-12-07 Cypress Semiconductor Corporation Method and apparatus for binding wireless devices
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2005019227A1 (en) * 2003-08-22 2005-03-03 Orchid Chemicals & Pharmaceuticals Ltd Process for the preparation of cephalosporin antibiotic
AU2006254897A1 (en) * 2005-06-06 2006-12-14 Fibrogen, Inc. Improved treatment for anemia using a HIF-alpha stabilising agent
GB0525164D0 (en) 2005-12-09 2006-01-18 Xention Discovery Ltd Compounds
BRPI0707302B8 (pt) * 2006-01-27 2021-05-25 Fibrogen Inc compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
WO2007097929A1 (en) 2006-02-16 2007-08-30 Fibrogen, Inc. Compounds and methods for treatment of stroke
BRPI0710527B8 (pt) * 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
CN101186611B (zh) 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
CN101186612B (zh) * 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
ES2393326T3 (es) 2006-12-18 2012-12-20 Amgen, Inc Compuestos basados en azaquinolona que presentan actividad inhibidora de prolil hidroxilasas, composiciones y usos de los mismos
US8048894B2 (en) 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
ES2446418T3 (es) 2007-04-18 2014-03-07 Amgen, Inc Derivados de indanona que inhiben la prolil hidroxilasa
US8030346B2 (en) 2007-05-04 2011-10-04 Amgen Inc. Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
EP2155746A2 (de) 2007-05-04 2010-02-24 Amgen, Inc Diazachinolone zur hemmung der prolylhydroxylaseaktivität
US8962530B2 (en) 2007-06-27 2015-02-24 Regents Of The University Of Colorado Inflammatory bowel disease therapies
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
KR20100045480A (ko) * 2007-08-10 2010-05-03 크리스탈지노믹스(주) 피리딘 유도체 및 이들의 사용방법
WO2009058403A1 (en) * 2007-11-02 2009-05-07 Fibrogen, Inc. Methods for reducing blood pressure
WO2009073669A1 (en) 2007-12-03 2009-06-11 Fibrogen, Inc. Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
EP2252619B1 (de) 2008-01-11 2013-10-09 Fibrogen, Inc. Isothiazolpyridinderivate als modulatoren der hif-(hypoxia-inducible-factor-)aktivität
WO2009100250A1 (en) 2008-02-05 2009-08-13 Fibrogen, Inc. Chromene derivatives and use thereof as hif hydroxylase activity inhibitors
AU2009217541A1 (en) * 2008-02-25 2009-09-03 Merck Sharp & Dohme Corp. Tetrahydrothieno pyridines
PT2294066E (pt) 2008-04-28 2014-11-21 Janssen Pharmaceutica Nv Benzoimidazoles como inibidores da prolil-hidroxilase
US8217043B2 (en) 2008-08-20 2012-07-10 Fibrogen, Inc. Compounds and methods for their use
WO2010024911A1 (en) * 2008-08-26 2010-03-04 Fibrogen, Inc. Methods for increasing neurogenesis
JP5649584B2 (ja) 2008-11-14 2015-01-07 フィブロジェン インコーポレイテッド Ｈｉｆヒドロキシラーゼ阻害剤としてのチオクロメン誘導体
WO2010110380A1 (ja) * 2009-03-27 2010-09-30 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
WO2012106472A1 (en) 2011-02-02 2012-08-09 Fibrogen, Inc. Naphthyridine derivatives as inhibitors of hypoxia inducible factor (hif) hydroxylase
GB201102659D0 (en) 2011-02-15 2011-03-30 Isis Innovation Assay
ITMI20110881A1 (it) * 2011-05-18 2012-11-19 E T C Srl Materiale semiconduttore organico
GB201113101D0 (en) 2011-07-28 2011-09-14 Isis Innovation Assay
TWI429652B (zh) 2011-08-05 2014-03-11 Ind Tech Res Inst 有機金屬化合物及包含其之有機電激發光裝置
US9079930B2 (en) 2011-09-23 2015-07-14 Merck Sharp & Dohme Corp. Substituted pyrimidines
EP2758058B1 (de) 2011-09-23 2017-04-26 Merck Sharp & Dohme Corp. Substituierte pyrimidine
WO2013063221A1 (en) 2011-10-25 2013-05-02 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1h-benzo[d]imidazol-2-yl)-1h-pyrazole-4-carboxylic acid
US9446031B2 (en) 2012-01-18 2016-09-20 National University Of Singapore Compositions and methods for neovascularization
WO2013134660A1 (en) 2012-03-09 2013-09-12 Fibrogen, Inc. 4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
AU2013290438C1 (en) 2012-07-16 2019-01-03 Kyntra Bio, Inc. Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid
US8883823B2 (en) 2012-07-16 2014-11-11 Fibrogen, Inc. Crystalline forms of a prolyl hydroxylase inhibitor
EP3219706A1 (de) 2012-07-16 2017-09-20 Fibrogen, Inc. Verfahren zur herstellung von isochinolinverbindungen
ITMI20121691A1 (it) 2012-10-09 2014-04-10 E T C Srl Materiale semiconduttore organico
ITMI20121939A1 (it) * 2012-11-15 2014-05-16 E T C Srl Materiale organico semiconduttore
ITMI20121952A1 (it) 2012-11-16 2014-05-17 E T C Srl Materiale semiconduttore organico
JO3781B1 (ar) * 2012-12-24 2021-01-31 Cadila Healthcare Ltd مشتقات الكينولون
AU2014209319B2 (en) 2013-01-24 2018-04-19 Fibrogen, Inc. Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
HRP20200615T1 (hr) 2013-06-06 2020-07-10 Fibrogen, Inc. Farmaceutske formulacije inhibitora hif hidroksilaze
WO2016034108A1 (zh) 2014-09-02 2016-03-10 广东东阳光药业有限公司 喹啉酮类化合物及其应用
CN109180580B (zh) 2016-02-28 2021-01-12 深圳市塔吉瑞生物医药有限公司 一种取代的杂芳基化合物及包含该化合物的组合物及其用途
RU2019104378A (ru) 2016-07-19 2020-08-19 Байер Кропсайенс Акциенгезельшафт Конденсированные бициклические гетероциклические производные в качестве средств для борьбы с вредителями
US12171741B2 (en) 2018-09-11 2024-12-24 Nikang Therapeutics, Inc. 2,3-dihydrobenzo[b]thiophene derivatives as hypoxia inducible factor-2(alpha) inhibitors
WO2020081695A1 (en) 2018-10-17 2020-04-23 Nikang Therapeutics, Inc. Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
CN111499654B (zh) * 2019-01-30 2022-09-02 南通诺泰生物医药技术有限公司 一种合成3-氯-噻吩[2,3,-b]吡啶衍生物的方法
IL287258B2 (en) 2019-04-18 2026-01-01 Nikang Therapeutics Inc Inhibitors as tetrahydro-1h-cyclopenta[cd] indene derivatives as hypoxia inducible factor -2alpha
CN110305143B (zh) * 2019-07-19 2021-03-09 济南新科医药科技有限公司 一种呋喃[2，3-c]并吡啶衍生物及其制备方法和用途
US11420936B2 (en) 2020-04-16 2022-08-23 Nikang Therapeutics, Inc. Hypoxia inducible factor-2(alpha) inhibitors and their use in the treatment of diseases
WO2021216530A1 (en) 2020-04-20 2021-10-28 Akebia Therapeutics, Inc. Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
WO2022150623A1 (en) 2021-01-08 2022-07-14 Akebia Therapeutics, Inc. Compounds and composition for the treatment of anemia
CN113234090B (zh) * 2021-04-23 2022-07-29 中国药科大学 靶向泛素化降解FoxM1的化合物或其可药用的盐、制备方法及用途
EP4347022A1 (de) 2021-05-27 2024-04-10 Keryx Biopharmaceuticals, Inc. Pädiatrische formulierungen von eisencitrat
US20230101768A1 (en) * 2021-08-13 2023-03-30 The Board Of Regents Of The University Of Texas System Method to treat manganese toxicity and manganese-induced parkinsonism in humans

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0650961T3 (da) 1993-11-02 1997-09-15 Hoechst Ag Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
ATE149485T1 (de) * 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
NZ270267A (en) 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
EP2335700A1 (de) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C Virus Polymerase Inhibitoren mit heterobicylischer Struktur
US7294457B2 (en) 2001-08-07 2007-11-13 Boehringer Ingelheim (Canada) Ltd. Direct binding assay for identifying inhibitors of HCV polymerase
DK2298301T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
WO2004108681A1 (en) 2003-06-06 2004-12-16 Fibrogen, Inc. Nitrogen-containing heteroaryl compounds and their use in increasing endogenous erythropoietin
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism

Also Published As

Publication number Publication date
WO2006094292A3 (en) 2006-12-28
EP1866318B1 (de) 2011-06-22
CN101166745A (zh) 2008-04-23
WO2006094292A2 (en) 2006-09-08
JP2008531736A (ja) 2008-08-14
EP1866318A2 (de) 2007-12-19
JP2011225583A (ja) 2011-11-10
US20140221422A1 (en) 2014-08-07
US9000006B2 (en) 2015-04-07
JP4792048B2 (ja) 2011-10-12
US8703795B2 (en) 2014-04-22
US20060199836A1 (en) 2006-09-07

Similar Documents

Publication Publication Date Title
ATE513833T1 (de) Thienopyridinverbindungen und verfahren zu ihrer verwendung
WO2007115315A3 (en) Pyrrolo- and thiazolo-pyridine compounds as hif modulators
ATE514755T1 (de) Fluoreszenzfarbstoffe zur verwendung bei der glukoseerfassung
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
ATE477249T1 (de) Heteroarylbenzamidderivate zur verwendung als glk-aktivatoren bei der behandlung von diabetes
DK1268847T3 (da) Ubiquitin-ligaseassay
EA200601303A1 (ru) Система ретрансляторов сигнала
EP1971366A4 (de) Menschliche anti-il-23-antikörper, zusammensetzungen, verfahren und verwendungen
NO20071127L (no) Triazoloftalaziner
EP1395113A4 (de) Verwendung von follistatin zur erhöhung der muskelmasse
ATE548391T1 (de) Gefangene bindungsproteine als biosensoren
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
MX2007008137A (es) Triazoloftalazinas como inhibidores de pde2.
ATE504836T1 (de) Verfahren zur identifizierung von trpv2- modulatoren
ATE512141T1 (de) Verwendung von tetrahydrobenzoxazinen als antioxidantien
ATE540755T1 (de) Verwendung von katalysatorzusammensetzungen und verfahren zur oxychlorierung
ATE448234T1 (de) Olanzapin-analoga und verfahren zu ihrer verwendung
DE602006004911D1 (de) Gasphasenoxidationskatalysator und dessen Verwendung zur Herstellung von Acrylsäure
ATE495243T1 (de) Verfahren zur herstellung von hochempfindlichen endonukleasen, neuartige zubereitungen von nukleasen und ihre verwendung
EA200801413A1 (ru) Гетероциклические сетр ингибиторы
ATE388635T1 (de) Verwendung von menadione zur verstärkung der wirksamkeit von agrochemikalien
ATE486878T1 (de) Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
ATE439831T1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
WO2006132739A3 (en) Novel chemical compounds
EP1885372A4 (de) Verwendung von prostacyclin-analogen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties